Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lymphoma
Biotech
J&J axes $5B CAR-T dream months after touting efficacy edge
Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliver peak sales north of $5 billion.
Nick Paul Taylor
May 1, 2026 8:26am
Innate's NK cell engager latest victim of pipeline refocus
Mar 26, 2026 5:20am
Regeneron does 180 on 2seventy lymphoma CAR-T
Oct 23, 2025 10:57am
Innate says lymphoma data shows anti-KIR3DL2 antibody’s promise
May 23, 2025 5:13am
Galapagos drops one CD19 CAR-T to focus on 'flagship' program
Feb 13, 2025 8:00am
RTW-built biotech's $520M deal for InnoCare, Keymed bispecific
Jan 21, 2025 4:32am
